Riskpilot← Back to searchSign inGet full accessGlaukos Sweden AB
ABActiveOrg 5590665583StockholmWholesale of pharmaceutical and medical goods · NACE 4646Est. 20164 employees
Revenue 2024
SEK 6,6M
-4% vs 2023
EBITDA margin
10.6%
+477% vs 2023
Equity ratio
28.8%
Financial strength
Net profit 2024
SEK 564K
+1384% vs 2023
| Revenue | SEK 6,6M | -4% |
| EBITDA | SEK 704K | +477% |
| Net profit | SEK 564K | +1384% |
| Total assets | SEK 5,1M | -10% |
| Equity | SEK 1,5M | +63% |
| Employees | 4 | — |
Legal name
Glaukos Sweden AB
Org number
5590665583
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
14 juni 2016
Share capital
SEK 50 000
Employees
4 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna suppleanterna
Company purpose
Bolaget skall marknadsföra och bedriva försäljning av medicin- tekniska produkter för behandling av glaukom och andra ögon- sjukdomar samt därmed förenlig verksamhet.
Address
Stockholm
Email
calle.hedenstrom@cfhlaw.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 6 391 | 7 896 | 8 190 | 6 902 | 6 635 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 420 | 168 | 344 | 122 | 704 |
| Depreciation & amort. | −2 | −0 | −0 | −0 | −0 |
| EBIT | 418 | 168 | 344 | 122 | 704 |
| Net financials | −91 | −80 | −80 | −83 | −140 |
| Profit before tax | 327 | 89 | 263 | 38 | 564 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | 327 | 89 | 263 | 38 | 564 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 7 166 | 9 106 | 9 701 | 5 626 | 5 084 |
| Equity | 511 | 599 | 863 | 901 | 1 465 |
| Long-term debt | 3 839 | 7 884 | 7 469 | 3 181 | 0 |
| Short-term debt | 2 816 | 622 | 1 369 | 1 544 | 3 619 |
| Total debt | 6 655 | 8 506 | 8 838 | 4 725 | 3 619 |
EBITDA margin
10.6%
This company
15.8%
Market median
-33% vs market
20202024
Equity ratio
28.8%
This company
38.2%
Market median
-25% vs market
20202024
Return on equity
38.5%
This company
18.4%
Market median
+109% vs market
20202024
Net profit margin
8.5%
This company
8.1%
Market median
+5% vs market
20202024
Asset turnover
1.31×
This company
1.12×
Market median
+17% vs market
20202024
Debt / equity
2.47×
This company
0.62×
Market median
-298% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
ES Audit | Audit | 2025 |
| Former (1) | ||
KY Chief Auditor | Chief Auditor | 2022 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Chairman | 2020 | |
| Deputy Board Member | 2025 | |
| Board of Directors | 2025 | |
| Deputy Board Member | 2020 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
GLAUKOS CORPORATION
Glaukos Sweden AB (this company)Board members of Glaukos Sweden AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kent Yngve Tommy Nilsson | Chief Auditor | 0 companies |
| Emine Sarihan | Audit | 0 companies |
| Thomas William Burns | Chairman | 0 companies |
| Joseph Edward Gilliam | Deputy Board Member | 0 companies |
| Lutz Temme | Board of Directors | 0 companies |
| Carl-Fredrik Hedenström | Deputy Board Member | 0 companies |